Peer-influenced content. Sources you trust. No registration required. This is HCN.
News Medical
Reductions in lean body mass are likely concentrated in non-contractile components rather than reflecting a clear decline in muscle function.
Endocrinology, Diabetes, Metabolism March 27th 2026
Healthline
“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine
Cardiology March 27th 2026
Medical Professionals Reference (MPR)
The approval was based on data from the randomized, double-blinded, parallel-group phase 3b STEP UP trial, which enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2, without diabetes.
Endocrinology, Diabetes, Metabolism March 26th 2026
Medical News Today (MNT)
“It gives clinicians objective clinical evidence guidance as to the risks and benefits of napping and catching up on sleep during weekends.” — Kaushik Govindaraju, DO, Medical Offices of Manhattan
Endocrinology, Diabetes, Metabolism March 16th 2026
Cardiology Advisor
The Wegovy tablet is the first oral GLP-1 receptor agonist indicated for weight loss and cardiovascular risk reduction in eligible adults.
Endocrinology & Diabetes Nursing March 13th 2026
GoodRx for Healthcare Professionals
If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.
Endocrinology, Diabetes, Metabolism March 13th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS